Virtual care provider Midi Health has raised $50 million in a Series C funding round led by Advance Venture Partners, bringing its total funding to around $150 million. The round, which closed in spring 2025, will support the company’s continued growth and expansion in women’s health.
Midi, which focuses on menopause and perimenopause care, now serves approximately 20,000 patients per week, nearly twice the number it supported in January 2025. CEO Joanna Strober said the company has also reached a $150 million revenue run rate, up from $60 million at the end of 2024.
The platform offers a range of personalised services, including hormonal and non-hormonal treatments, blood and genetic testing, lifestyle coaching and supplements. It works with major commercial insurers such as UnitedHealthcare, Cigna and Aetna, though it does not currently accept Medicare or Medicaid plans.
Midi is also developing an AI-powered search engine for women’s health, with Strober noting that existing medical search tools can be inaccurate and outdated sometimes, when it concerns women’s health. Additionally, the company launched AgeWell in May 2025, a preventive care programme focusing on cardiovascular disease, cancer prevention, and bone and brain health.
Previous investors include Emerson Collective, GV, and angel investors such as 23andMe cofounder Anne Wojcicki, Amy Schumer, and Tory Burch. Midi raised $60 million in its Series B round in April 2024.
The latest funding will be used to advance technology development and expand its clinical team. Strober added that while Midi “has a clear path to profitability,” there are no immediate plans for an IPO.
